Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 3/20 | 0.51 |
| ▸ | DCPS | Q96C86 | 10/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2165229 | 0.91 | DCPS (0.49) | DHFRDCPSCYP2D6DRD3KDM4E | |
| SCHEMBL2165621 | 0.88 | KCNA5 (0.57) | DHFRDCPSCYP2D6LDHADRD3 | |
| SCHEMBL2165732 | 0.83 | DCPS (0.69) | DHFRDCPSCYP2D6 | |
| SCHEMBL2166072 | 0.83 | MEN1 (0.57) | DHFRDCPSLDHADRD3DRD2 | |
| SCHEMBL2164716 | 0.82 | DCPS (0.72) | DHFRDCPSCYP2D6 | |
| SCHEMBL2165290 | 0.81 | DCPS (0.54) | DHFRDCPSDRD3DRD2KCNA5 | |
| SCHEMBL2166531 | 0.80 | DCPS (0.52) | DHFRDCPSCYP2D6KDM4EALDH1A1 | |
| SCHEMBL2164770 | 0.79 | KCNH2 (0.48) | DHFRDCPS | |
| SCHEMBL2165589 | 0.79 | DRD2 (0.52) | DCPSCYP2D6DRD3KDM4EALDH1A1 | |
| SCHEMBL15284096 | 0.78 | DCPS (0.55) | DHFRDCPSCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985755-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-07-26 | — | — | US | claimed |
| EP-2069316-B1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2015-10-07 | — | — | EP | disclosed |
| US-7985755-B2 | 2,4-diaminoquinazolines for spinal muscular atrophy | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2011-07-26 | — | — | US | disclosed |
| EP-2069316-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | Families of Spinal Muscular Atrophy (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | DECODE CHEMISTRY, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008016973-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | FAMILIES OF SPINAL MUSCULAR ATROPHY (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042900-A1 | 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY | SMN1; SMN2, MUSK, MYT1 | DHFR 1446/4885DCPS 1366/4885CYP2D6 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.